HK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program

Stock News

Oct 31

FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) for its Enzalutamide Soft Capsule. The drug is approved for treating adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and show no or mild symptoms without prior chemotherapy.

Additionally, FUSEN PHARM disclosed that its Metformin Empagliflozin Tablet (I) (containing 500mg metformin hydrochloride and 5mg empagliflozin) has been preliminarily selected in China's 11th national bulk drug procurement program. The company had previously announced in September that the NMPA had approved the market application for this product.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1177679917"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177679917\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177679917?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 10:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177679917","market":"us","top_or_hot":-1,"title":"HK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program","media":"Stock News","content":"<p>FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) for its Enzalutamide Soft Capsule. The drug is approved for treating adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and show no or mild symptoms without prior chemotherapy.</p>\n<p>Additionally, FUSEN PHARM disclosed that its Metformin Empagliflozin Tablet (I) (containing 500mg metformin hydrochloride and 5mg empagliflozin) has been preliminarily selected in China's 11th national bulk drug procurement program. The company had previously announced in September that the NMPA had approved the market application for this product.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-31 10:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) for its Enzalutamide Soft Capsule. The drug is approved for treating adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and show no or mild symptoms without prior chemotherapy.</p>\n<p>Additionally, FUSEN PHARM disclosed that its Metformin Empagliflozin Tablet (I) (containing 500mg metformin hydrochloride and 5mg empagliflozin) has been preliminarily selected in China's 11th national bulk drug procurement program. The company had previously announced in September that the NMPA had approved the market application for this product.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01652","symbol_name":"福森药业","start_time":0,"source_url":"","article_id":"1177679917","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177679917","pubTimestamp":1761878056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01652":"福森药业","BK1191":"制药"},"translate_title":"港股动向|福森药业(01652)盘中大涨近74%因恩杂鲁胺软胶囊获批、二甲双胍恩格列净片纳入国家带量采购计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01652":1},"content_text":"FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) for its Enzalutamide Soft Capsule. The drug is approved for treating adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and show no or mild symptoms without prior chemotherapy.\nAdditionally, FUSEN PHARM disclosed that its Metformin Empagliflozin Tablet (I) (containing 500mg metformin hydrochloride and 5mg empagliflozin) has been preliminarily selected in China's 11th national bulk drug procurement program. The company had previously announced in September that the NMPA had approved the market application for this product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}